Osiris Therapeutics, Inc. (OSIR) Expands Its Grafix® Product Portfolio And Launches Additional Sizes
7/17/2014 11:10:20 AM
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced the addition of several new sizes to the Grafix® product line. Grafix, a cryopreserved placental membrane, is regulated under 21 CFR 1271, part 361, Human Cells, Tissues and Cellular Tissue-Products (HCT/Ps) as a wound cover. Like other HCT/Ps, Grafix can be manufactured in multiple sizes, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is now available in five convenient sizes and is very well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system.
Help employers find you! Check out all the jobs and post your resume.
comments powered by